karuna initi outperform
initi outperform rate pt view
emerg leader schizophrenia psychosi lead develop candid
karxt coformul xanomelin trospium chlorid base novel
differenti moa target muscarin receptor strong clinic data believ
uniqu moa karxt enabl potenti superior efficaci toler
current avail atyp antipsychot compris market
primarili develop karxt schizophrenia adult dementia-rel psychosi
drp pivot program schizophrenia expect initi
follow compel result safeti studi drp reads-out
estim peak sale schizophrenia drp
karxt oral coformul xanomelin novel muscarinic-receptor
agonist allevi psychosi symptom combin trospium
chlorid fda-approv muscarinic-receptor antagonist without blood-brain
barrier penetr amelior cholinerg side-effect xanomelin
peripheri tissu preserv efficaci within brain xanomelin
origin develop two trial demonstr remark efficaci
schizophrenia drp includ cognit benefit
schizophrenia patient would benefit differenti moa potenti
efficaci safeti advantag karxt result strongli posit
panss score reduct pt karxt vs placebo
signific efficaci neg cognit symptom favor toler
plan fda initi estim
peak risk-adjust sale
drp occur across dementia subtyp remain larg unmet need
avail therapi clinic practic involv off-label use antipsychot despit
black-box warn danger outcom elderli patient xanomelin
data demonstr compel efficaci pimavanserin provid
regulatori preced expect elderli safeti data
estim peak risk-adjust sale
antipsychot market size world-wide sale reflect larg
opportun competit new entrant novel treatment profil view
sunovion potenti competitor believ
karxt uniqu moa provid distinct advantag efficaci toler
assum karxt schizophrenia launch drp launch
pt base dcf valuat methodolog sotp analysi valu
schizophrenia drp believ current share price
repres attract entri point ahead key catalyst initi outperform
year price histori
karuna inc clinical-
cholinerg receptor treat numer
headquart boston
juli
analyst certif import disclosur see disclosur
schziophrenia pivot result posit
success launch schizophrenia treatment set
regulatori preced drp indic
partnership ex-u commerci
better expect clinic data readout
higher estim peak sale
view leader schizophrenia neuropsychiatr
disord lead clinic develop candid karxt
receptor believ uniqu moa enabl potenti
superior current avail antipsychot view
well-capit ahead expect pivot program
karxt schizopjhrenia follow strong result
unexpect safeti signal karxt
failur clinic trial endpoint
lower expect product sale
higher anticip competit
legal challeng intellectu properti
price target base dcf valuat methodolog estim wacc believ
adequ reflect risk associ predominantli single-asset compani residu growth rate due assum
patent expir karxt estim total risk-adjust peak sale across indic
key downsid risk price target clinic develop risk regulatori risk karxt current pend pivot
develop stage addit risk aris lower-than-expect peak sale estim due higher-than-anticip competit
failur gain support medic commun healthcar prescrib third-parti payor risk relat legal
challeng patent protect karxt
initi coverag karuna therapeut inc outperform rate
price target view emerg leader schizophrenia psychosi
treatment lead develop candid karxt karuna-xanomeline-trospium
base novel differenti mechan action moa strong clinic data
karxt combin xanomelin trospium chlorid respect maxim efficaci
psychosi symptom reduct minim advers side effect believ
uniqu moa enabl potenti superior current avail antipsychot
compris market anticip focu primarili develop karxt
indic schizophrenia adult follow dementia-rel psychosi drp
estim peak sale schizophrenia drp appli
probability-of-success po risk adjust schizophrenia drp
price target base dcf valuat methodolog
karxt oral coformul xanomelin muscarinic-receptor preferenti
agonist reduc symptom psychosi combin trospium chlorid
muscarinic-receptor antagonist without blood-brain barrier bbb penetr
amelior on-target cholinerg side-effect xanomelin peripheri tissu
maintain efficaci within brain view karxt moa valid previou
xanomelin monotherapi therapi trial conduct demonstr efficaci
fda-approv trospium chlorid overact bladder clinic studi karxt
conduct support substanti improv toler profil
preserv efficaci confid potenti path approv schizophrenia
base strong result highli statist signific clinic meaning
posit neg syndrom scale panss score total mean reduct vs
placebo safeti toler compar favor standard-of-car
soc antipsychot secondari endpoint panss posit neg symptom
subscal score also achiev statist signific believ compel
result de-risk pivot program anticip initi follow
plan meet fda plan initi addit
studi karxt schizophrenia cognit neg symptom support
clinic profil drp view lli random trial xanomelin monotherapi
alzheim diseas ad psychosi encourag posit efficaci despit
toler concern anticip on-going trial karxt healthi elderli
volunt achiev suffici improv toler data expect
atyp antipsychot second-gener antipsychot sga market size
world-wide annual sale current exampl abilifi seroquel
zyprexa reach histor peak sale provid basi refer market
forecast karxt note legaci moa target dopaminerg and/or serotoninerg
neurotransmitt receptor induc advers side-effect somnolence/sed
extrapyramid symptom ep and/or weight gain believ karxt
highli competit fresh market entrant schizophrenia entir new moa
base substanti improv toler even efficaci perceiv similarli
high refractori rate impli patient demand novel differenti
altern view efficaci neg cognit symptom key competit
advantag sga either demonstr improv may even exacerb
symptom addit valu could aris potenti spontan use karxt
combin view main competitor karxt caplyta nuplazid
roluperidon sunovion although note distinct advantag
karxt base clinic data moa note set regulatori preced
drp indic view drp larg opportun wide-open market
believ becom market leader karxt schizophrenia
drp potenti expans pain neuropsychiatr disord
valu dcf methodolog use discount rate reflect risk
believ associ predominantli single-asset compani termin valu
growth rate base patent expir arriv price target
estim total peak sale across indic appli
respect po risk adjust forecast revenu estim cash balanc
cash burn expect runway next three year
addit sotp analysi valu karxt schizophrenia drp
model pipelin expans karxt pain combin
and/or possibl indic provid potenti sourc addit upsid
forecast world-wide peak sale karxt schizophrenia base
market model schizophrenia patient estim schizophrenia adult
patient us diagnosi rate refractori rate soc therapi
defin address us patient popul karxt set
estim peak market penetr initi us annual net price
base nuplazid assum ex-u partnership royalti
po schizophrenia base recent complet trial strongli
posit result larg unmet need schizophrenia therapi efficaci
posit neg cognit symptom clean safeti toler profil
literatur histor trial psychiatri forecast launch estim
peak risk-adjust world-wide sale
forecast world-wide peak sale karxt drp base
market model drp patient estim elderli dementia patient us
diagnosi rate preval psychosi symptom defin
address us patient popul estim peak market penetr
initi us annual net price equival karxt price schizophrenia
assum ex-u partnership royalti po drp base
support prior data pend toler data trial regulatori preced set
literatur histor trial psychiatri forecast launch
estim peak risk-adjust world-wide sale
key downsid risk price target clinic develop risk regulatori risk
karxt current pend pivot develop stage addit risk aris
lower-than-expect peak sale estim due higher-than-anticip competit
failur gain support medic commun healthcar prescrib third-
parti payor risk relat legal challeng patent protect karxt
upsid potenti price target aris better expect clinic data
readout plan on-going clinic trial higher estim peak sale
accret pipelin expans favor licens deal potenti acquisit
initi addit studi cognit neg symptom initi
schizophrenia data elderli healthi volunt drp forecast
schizophrenia pivot readout file launch
drp potenti pivot trial file launch
krtx share price perform current sinc ipo
vs nbi note return
follow announc posit result kartx schizophrenia contribut
total return ipo vs nbi rank
top-perform biotechnolog ipo vs weighted-averag
rais ipo net proce addit secondari
offer net proce share nov financ anticip
registr develop ownership primarili consist found vc investor
puretech health ventur partner sofinnova ventur
addit larg institut investor includ fidel row price
ceo/chairman steve paul own share outstand float
short interest float recent averag volum
share view current trade market cap reflect
exhibit share price perform current ownership roster
note past perform view guarante futur result note return calcul exclud applic cost includ commiss interest
timingasset fda symptom studi symptom studi data elderli healthi pivot program initi
karuna inc clinical-stag biopharmaceut compani focus
develop commerci therapi neuropsychiatr disord
found juli puretech health headquart boston krtx
lead product candid karxt combin xanomelin trospium chlorid
respect maxim efficaci reduc psychosi symptom minim
advers side-effect primarili focus execut late-stag clinic
develop karxt treatment schizophrenia secondarili focus drp
potenti indic includ pain rais net proce
ipo share rais net secondari offer
share nov follow posit data anticip
cash balanc provid runway
karxt oral coformul xanomelin muscarinic-receptor preferenti
agonist reduc symptom psychosi combin trospium chlorid
muscarinic-receptor antagonist without bbb penetr amelior on-
target cholinerg side-effect xanomelin peripheri tissu maintain efficaci
within brain muscarin receptor g-protein coupl receptor gpcr bind
neurotransmitt acetylcholin modul neuron excit impli role
etiolog psychosi disord xanomelin origin develop
ceo chairman steve paul formerli treatment psychosi
relat neuropsychiatr disord studi patient across trial
includ two random placebo-control trial alzheim diseas
schizophrenia demonstr efficaci psychosi symptom reduct
cognit improv howev cholinerg side-effect xanomelin limit
therapeut potenti monotherapi co-found andrew miller formerli
puretech health initi hypothes combin muscarinic-receptor agonist
antagonist improv toler preserv efficaci assess potenti
combin discov optim pair xanomelin trospium chlorid
found develop karxt licens agreement puretech
sinc complet dose optim studi random
placebo-control studi posit result read-out
studi karxt schizophrenia patient acut psychosi demonstr
highli statist signific clinic meaning result improv
panss total score compar placebo favor toler secondari
endpoint includ panss posit neg symptom subscal also
statist signific current prepar fda meet
ahead pivot program anticip initi also plan initi
trial schizophrenia cognit neg symptom drp
expect top-lin data karxt elderli healthi volunt read-out
exhibit pipelin anticip upcom mileston
mechan action
karxt oral coformul xanomelin muscarinic-receptor preferenti
agonist trospium chlorid muscarinic-receptor antagonist peripheri
tissu without bbb penetr muscarin acetylcholin receptor machr system
involv transduct cholinerg signal central nervou system
autonom ganglia smooth muscl parasympathet organ implic
function etiolog schizophrenia variou neuropsychiatr disord
machr g-protein coupl receptor gpcr neurotransmitt acetylcholin
consist five isoform machr seven-transmembran protein
divid two major function class base g-protein coupl
coupl gq protein activ phospholipas subsequ releas
intracellular store stimul protein kinase-c promot channel closur
result intracellular mapk plc pathway signal drive cellular excit
subtyp coupl gi/o protein inhibit adenyl cyclas caus
decreas intracellular camp level promot inhibit voltage-g
channel overal decreas cellular excit machr signal involv
cross-talk variou receptor consequ promot open close
 cl- channel might facilit either depolar hyperpolar
depend cell type receptor express induc pleiotrop effect
predominantli express wide
distribut peripher tissu primari isoform express
locat dens striatum postsynapt cell bodi
dendrit hippocamp pyramid neuron granul cell cortex layer
activ potenti glutamaterg system nmda current hippocampu
prefront cortex regul memori learn execut function support
rational agon improv cognit behavior neg symptom
wide distribut across brain region includ cortex hippocampu
primarili locat striatum express presynapt autoreceptor
striatal cholinerg interneuron midbrain project neuron postsynapt
modulatori receptor striatum neocortex hippocampu ideal locat
activ inhibit downstream dopaminerg pathway allevi psychosi
xanomelin emerg potenti therapeut applic machr activ
support dose-depend efficaci lli initi clinic studi howev
efficaci benefit limit cholinerg side-effect includ gastrointestin cramp
saliv vomit like result peripher machr activ
trospium chlorid antagon machr cholinerg innerv organ
peripheri tissu hydrophil neglig bbb penetr clear renal
karxt complet novel approach combin xanomelin trospium chlorid
preserv efficaci activ favor toler
exhibit moa karxt combin xanomelin trospium chlorid
schizophrenia chronic neuropsychiatr disord estim preval
adult equat popul us patient total world-wide patient
patient sever mental disabl reduc life-expect year
schizophrenia defin three primari symptom cluster posit symptom neg
symptom cognit deficit posit symptom involv distort present mental
function psychosi character auditori hallucin delus
paranoia disorgan speech behavior neg symptom involv absenc
mental function otherwis present healthi individu characterist exampl
includ blunt flat affect social withdraw alogia diminish fluenci languag
anhedonia appar inabl feel pleasur avolit lack motiv
posit symptom conspicu caregiv often prompt initi diagnosi
treatment especi patient experi acut exacerb symptom
untreat underli like progress psychosi at-risk patient base
current sever neg symptom often preclud patient work social
live independ manag everyday task cognit deficit schizophrenia
patient may present attent impair work episod memori deficit
execut function disrupt similarli persist prior emerg posit
symptom often becom identifi first episod acut psychosi
symptom includ mood affect symptom includ depress anxieti
irrit well behavior aggress symptom includ abus self-harm
destruct behavior despit mani avail treatment sever aspect
schizophrenia remain larg unmet medic need treat neg
diseas progress schizophrenia begin mild deficit social motor
cognit function early-adolesc premorbid stage follow gradual
onset posit neg symptom late-adolesc prodrom stage
preempt psychot episod eventu result diagnosi pathophysiolog
involv structur chang brain includ decreas integr grey white
matter declin rate glutam signal reduct brain-tissu volum
prefront cortex pfc suggest subsequ progress abnorm function
connect brain region especi pfc functional-mri studi examin
early-stag patient show hyper-connect pattern pfc hippocampu
brain region later appear diminish time diseas progress
associ shift excitation-to-inhibit balanc critic pfc circuit
prevail hypothes identifi disrupt dopaminerg glutamaterg pathway
differ brain region induc specif symptom schizophrenia
exhibit clinic pathophysiolog cours schizophrenia diseas progress
dopamin hypothesi suggest hyperactiv dopaminerg mesolimb
nigrostriat pathway via stimul induc posit symptom
hypoactiv dopaminerg mesocort frontal cortic pathway via reduc
stimul induc neg symptom cognit deficit hypothesi
drove initi therapeut develop antagonist follow
serotonergic-receptor antagonist lower antagon antipsychot
glutam hypothesi later ad hypoactiv nmda receptor gaba
interneuron within cortex ventral hippocampu disinhibit glutamaterg pathway
induc hyperactiv dopaminerg mesolimb nigrostriat pathway
hypoactiv dopaminerg mesocort frontal cortic pathway accordingli
therapeut potenti exist nmda-receptor agonist machr agonist
potenti nmda current promisingli offer pleiotrop pharmacolog approach
simultan address posit neg cognit symptom
exhibit neurobiolog underli pathophysiolog schizophrenia
diagnosi schizophrenia outlin fifth edit diagnost statist
manual mental disord sinc schizophrenia heterogen clinic
syndrom present rang cognit behavior emot dysfunct
singl symptom pathognomon disord practic diagnosi involv
recogn constel sign symptom associ impair occup
social function criterion-a symptom must present longer
criterion-b involv identif specif impair function criterion-c
specifi longer period persist criterion-b impair diagnosi
typic occur late-adolesc prodrom stage posit symptom
emerg sever becom appar estim overal diagnosi rate
exhibit diagnost criteria schizophrenia diseas progress timelin
american psychiatr associ yasui-furukori et al drug design develop therapi
treat psychosi posit symptom consist dopamin hypothesi
suggest degre bind determin therapeut risk/benefit ratio
side-effect off-set efficaci fga degre bind
mesolimb pathway need efficaci occup
dorsal striatum induc ep tardiv dyskinesia td chronic use
pituitari induc hyperprolactinemia antagon mesolimb
pathway allevi posit symptom may exacerb affect symptom
mesocort pathway may exacerb neg cognit symptom fga also may
affin muscarin histaminerg noradrenerg receptor contribut
overlap side-effect cognit deficit sedat first fga discov
antihistamin chlorpromazin phenothiazin serendipit observ
neurolepsi anim fga develop gener classifi
potenc strength dilemma antagon risk/benefit ratio drove eventu
pharmacolog develop atyp antipsychot therapi
exhibit moa limit first-gener antipsychot fga
atyp antipsychot sga improv upon clinic risk/benefit profil fga
primarili antagon serotonerg receptor exhibit divers pharmacolog
bind affin toward multipl receptor target includ dopaminerg serotonerg
histaminerg muscarin adrenerg receptor along activ transport
serotonin receptor antagon glutamaterg
cortic pyramid neuron prevent gaba releas therebi disinhibit downstream
dopamin releas nigrostriat pathway sinc increas dopamin compet
antagon striatum requir occup reduc
suffici lower ep hyperprolactinemia risk still provid efficaci howev
rel ratio bind affin entir off-set ep risk mani
sga induc metabol side-effect weight gain hyperglycemia dyslipidemia
risk like aris divers pharmacolog although risk type degre
vari across sga includ black-box warn use elderli drp patient
first-ev clozapin soc treatment-resist schizophrenia exampl
recent sga abilifi aripiprazol seroquel quetiapin zyprexa olanzapin
exhibit moa limit second-gener antipsychot sga
exhibit classif antipsychot clinic pharmacolog profil
prescrib antipsychot heterogen schizophrenia popul complex
differ clinic trial set psychiatrist often modifi dosag prescrib
multipl drug clinic trial head-to-head comparison monotherapi
and/or placebo mani patient receiv combin may eventu switch regimen
switch problemat given overlap pharmacolog profil could induc
side-effect includ agit insomnia relaps psychosi recommend
treatment algorithm patient becom treatment-resist mani patient also
elect discontinu initi prescript due intoler adher prescrib
sga measur cati studi sponsor nimh found
patient discontinu medic within month start new
regimen conclud major discontinu due inefficaci
intoler base establish guidelin psychiatrist treatment algorithm
schizophrenia involv decid initi prescript assess core symptom
sever posit neg symptom panss scale score
symptom affect behavior rel pharmacolog profil switch base
assess symptom persist
side-effect
manag four week dose prescrib clozapin anoth agent
set combin therapi estim rate treatment-resist
drive popul diagnos schizophrenia patient set
believ novel agent could potenti enter treatment paradigm
initi prescript base
reimburs recommend brand product rais bar novel
agent potenti move earlier line treatment
intoler need
exhibit cati trial outcom treatment algorithm side-effect manag
lieberman et al nejm mima guidelin treat schizophrenia
bind affin aripiprazol abilifi //// /// asenapin saphri brexpiprazol rexulti /// //// cariprazin vraylar -/// /// clozapin clozaril /// iloperidon fanapt // lurasidon latuda -- olanzapin zyprexa paliperidon invega pimavanserinnuplazid -- -- -- quetiapin seroquel risperidon risperd ziprasidon geodon /// note strong bind ki nm strong bind nm ki nm moder bind nm ki nm weak bind nm ki nm weak neglig bind ki nm partial agonist use denot rel bind valu instead karuna
dementia chronic neuropsychiatr disord estim preval
elderli adult age equat us patient total world-wide patient
preval consist alzheim diseas ad vascular dementia
lewi bodi dementia ldb frontotempor dementia ftd subtyp
dementia-rel psychosi drp broadli defin syndrom psychot symptom
emerg estim preval across dementia patient subtyp
dementia defin neurodegen declin memori cognit function
drp sever increas correspondingli pathophysiolog diseas progress
drp primarili involv persist increas frequenc psychosi symptom
character predominantli delusion misidentif visual hallucin
behavior symptom character agit aggress patient often
debilit drp symptom underli cognit declin dementia
outcom may includ constant caregiv attent nurs home care hospit
increas mortal caregiv burden substanti becom compound
patient conscious unawar symptom may occur symptom
drp remain entir unmet medic need without disease-modifi therapeut
dementia current avail pharmacolog treatment symptom
diseas progress drp coincid neurodegen patholog dementia
psychosi behavior symptom necessarili epiphenomenon specif
neuropatholog within one dementia subtyp rather emerg consequ
complex patholog overlap across subtyp reveal similar synapt pathway
dysfunct brain region correspond specif drp symptom neurodegener
dementia viz ad hypothes consequenti neurotox fibrillar deposit
aggreg plaqu phosphoryl tau neocortex patholog
cognit declin although drp emerg rapidli earli middl stage diseas
impli presenc factor neuro-inflamm microgli activ contribut
synaps dysfunct neuroimag studi ad psychosi indic
reduct neocort synapt structur function rel ad without psychosi
includ evid reduc perfus metabol lower gray matter densiti also
evid suggest comorbid patholog lewi bodi inclus
vascular lesion overlap psychosi risk ad trial xanomelin
like includ patient dementia subtyp given screen plaqu
suggest patholog correl drp overlap loss cholinerg neuron
basal forebrain impair presynapt acetylcholin synthesi cortex
hippocampu intriguingli receptor nonetheless maintain drp brain
like explain posit clinic efficaci xanomelin includ cognit benefit
diagnosi drp occur dementia diagnosi onset cognit declin
exhibit clinic pathophysiolog cours drp diseas progress
et al lancet neurol krivinko et al geriatr psychiatri gottesman stern front pharmacol
pathophysiolog drp similarli schizophrenia involv synapt dysfunct along
dopaminerg serotonerg glutamaterg cholinerg pathway across brain region
result specif psychosi symptom glutam hypothesi drp explain
ndma hypofunct cerebr cortic ventral hippocampu plaqu
tau and/or lewi bodi neuropatholog like preval reduc glutamaterg input
ndma receptor gaba interneuron lower gabaerg input downstream
glutamaterg pathway becom disinhibit therebi induc hyperactiv
dopaminerg mesolimb pathway caus psychot symptom pharmacolog
target nmda receptor via agonist accordingli improv psychosi
circumv ep side-effect associ dopamine-receptor antagon
pimavanserin serotonerg receptor preferenti antagonist provid efficaci
psychosi view xanomeline-target glutamaterg cholinerg pathway
superior rational allevi psychosi well improv cognit function
exhibit neurobiolog underli pathophysiolog drp
clinic practic current appli off-label use fga sga despit black-box
warn use drp patient sga often modest equivoc efficaci
may even acceler cognit declin induc danger off-target toxic
risk/benefit profil sga drp patient measur catie-ad studi
sponsor nimh found time treatment discontinu due
intoler significantli favor placebo signific differ
found placebo group improv clinic global impress chang
cgic scale measur psychosi behavior symptom conclud
neg risk/benefit common off-target dose-limit side-effect sga
drp patient includ ep orthostat hypotens potenti caus syncop
hematolog abnorm metabol side-effect could serious
harm elderli popul sga pharmacolog class therefor
black-box warn increas risk mortal drp patient sga also may
acceler declin cognit function via dopaminerg receptor antagon reflect
unmet need novel pharmacolog
exhibit catie-ad trial outcom treatment algorithm common side-effect
xanomelin machr preferenti agonist origin develop
ceo chairman steve paul formerli treatment
psychosi relat neuropsychiatr disord xanomelin histor clinic data
consist patient across trial includ two random placebo-control
trial alzheim diseas schizophrenia demonstr
efficaci psychosi symptom reduct improv cognit function
howev xanomelin found induc cholinerg side-effect peripher tissu viz
nausea vomit gi distress limit potenti use monotherapi
formerli puretech health initi hypothes combin machr agonist
antagonist substanti improv toler preserv efficaci
assess potenti combin discov optim pair xanomelin
trospium chlorid machr antagonist approv overact bladder
develop karxt oral coformul xanomelin trospium chlorid
schizophrenia adult drp complet toler dose studi
random placebo-control trial schizophrenia posit result
read-out anticip meet fda design
pivot program initi also plan initi trial
schizophrenia cognit neg symptom studi karxt elderli
healthi volunt drp on-going expect top-lin data
exhibit summari clinic develop xanomelin karxt
trial xanomelin psychot symptom agit ad
conduct random double-blind placebo-control trial xanomelin
patient mild/moder alzheim diseas patient random
ratio across three dose-rang cohort placebo dose administr
xanomelin tid tid tid placebo
week follow single-blind placebo washout efficaci result includ
dose-depend reduct psychot symptom behavior includ hallucin
delus agit xanomelin vs placebo respons observ
earli week treatment observ statist signific respons
remiss hallucin high-dos patient vs placebo
patient efficaci also demonstr reduct emerg
psychot symptom patient without psychot symptom baselin emerg
delus observ tid patient vs placebo patient
analysi dose-respons demonstr increas effect size xanomelin
across multipl psychosi symptom addit observ efficaci
cognit symptom treat patient measur adas-cog cibic score
respect measur cognit function behavior sever efficaci result
demonstr statist signific effect adas-cog improv
high-dos vs placebo compar effect donepezil approv
cognit impair ad effect cibic high-dos vs placebo
exhibit trial xanomelin ad psychosi efficaci result
safeti toler profil xanomelin first demonstr
differenti favor compar fga sga observ ep
weight gain sedat although observ high dose-depend incid
on-target cholinerg side effect discontinu rate low-dos
mid-dos high-dos cohort compar placebo patient notabl
xanomelin demonstr efficaci statist signific despit limit
statist power discontinu primarili driven toler concern
common advers event relat treatment tr high-dos arm
cholinerg side effect sweat nausea vomit dyspepsia dose-
depend trae predominantli gi-rel syncop observ
high-dos patient vs placebo rapid recoveri observ syncop
episod without need extraordinari medic attent note major
observ trae occur within first month treatment placebo
exhibit trial xanomelin ad psychosi safeti result
view trial xanomelin psychot symptom agit ad patient
support potenti indic karxt drp current trial
assum substanti improv safeti toler especi syncop critic
elderli patient avail therapi drp anticip acad
pimavanserin receiv fda approv base harmoni result
statist signific reduct risk psychosi relaps believ
would ultim design similar trial view regulatori preced favor
trial xanomelin psychot symptom schizophrenia
collabor indiana univers school medicin conduct random
double-blind placebo-control trial xanomelin patient schizophrenia
experienc acut psychosi hospit diagnosi criteria base
dsm-iv confirm second clinic interview conduct psychiatrist
inclus criteria requir adult total panss score least
one posit symptom item two posit symptom item prior
enrol two patient antipsychot treatment patient
sga six patient fga patient exhibit poor respons
symptom worsen treatment requir undergo day washout
preced random either xanomelin placebo group dose administr
enabl titrat daili tid day primari endpoint chang
panss score day baselin vs placebo efficaci result demonstr
statist signific clinic meaning chang panss score
xanomelin vs placebo addit demonstr improv
posit symptom subscal improv neg symptom subscal
efficaci also includ statist signific improv clinic outcom earli
measur total mean brief psychiatr rate scale bpr xanomelin vs
placebo also observ statist signific efficaci improv
delay memori xanomelin vs placebo
exhibit trial xanomelin schizophrenia efficaci safeti result
observ frequent xanomelin treatment group patient
gener favor mild/moder sever transient
result studi discontinu observ signific chang blood pressur
heart rate ecg measur notabl signific chang ep measur
simpson-angu rate scale barn rate scale drug-induc ankathisia
aim observ common nausea vomit gi-distress
consist cholinerg side-effect observ prior trial
xanomelin psychot symptom ad patient includ syncop given
lower averag patient age discontinu rate xanomelin
treatment group placebo due lack efficaci studi
male patient age previous unrespons prior fga sga enrol
panss score baselin experienc improv xanomelin
day includ improv posit neg symptom subscal
reportedli experienc last psychiatr stabil month conclud
despit small sampl size trial demonstr potenti xanomelin treat
multipl symptom domain patient schizophrenia
pilot studi karxt volunt
poc studi xanomelin monotherapi vs xanomelin combin trospium chlorid
 karxt healthi volunt studi design compar safeti toler
profil pharmacokinet pk xanomelin administ placebo karxt
co-administ xanomelin combin trospium chlorid dose administr
first receiv daili bid trospium chlorid placebo two day
addit receiv daili tid xanomelin seven day
select dose base result ad schizophrenia trial
xanomelin observ addit trospium chlorid xanomelin
associ clinic meaning reduct frequenc common
cholinerg advers event chae includ nausea vomit diarrhea sweat
saliv observ two trial compar xanomelin plu placebo
result demonstr overal rate xanomelin placebo vs
karxt addit rate subject receiv karxt similar
rate observ subject receiv placebo lead-in period
suggest toler profil karxt similar placebo compar
xanomelin plu placebo safeti measur heart rate blood pressur ecg
paramet observ meaning differ karxt xanomelin
plu placebo discontinu rate low one subject discret discontinu
due trae karxt syncop observ two subject xanomelin plu
placebo none observ subject karxt postur dizzi rate
reduc subject karxt vs xanomelin plu placebo overal major
chae observ mild transient suggest karxt substanti
improv upon toler profil xanomelin monotherapi
exhibit pilot studi karxt design safeti result
multipl ascend dose studi karxt volunt
dose mad studi karxt healthi volunt studi design evalu safeti
toler profil pk karxt bid dose contain fix ratio xanomelin
trospium chlorid explor higher dose compar previou studi
evalu karxt dose xanomelin tid plu bid trospium chlorid base
dose-depend efficaci observ trial improv toler karxt
subject random karxt across three dose-rang cohort placebo
dose administr xanomelin plu trospium chlorid bid
placebo day bid bid bid
placebo day observ karxt contain bid xanomelin dose
provid exposur measur plasma level equival greater
exposur tid xanomelin monotherapi observ previou studi
safeti toler profil bid bid karxt consist
exhibit mad studi karxt safeti result
result demonstr xanomelin well-toler bid bid
respect combin bid bid trospium chlorid notabl
observ bid karxt subject report chae
report mild transient chae major chae
report longest durat total day treatment
moder sever chae observ subject longest
last day treatment conclud bid karxt
dose well-toler base data addit observ
bid karxt subject report chae report mild
transient chae last day treatment observ
bid trospium chlorid higher dose associ higher incid mild
anticholinerg viz dry-mouth constip blur vision urinari hesit
suggest lower dose bid optim combin bid xanomelin
bid xanomelin highest dose increas incid moder chae
therefor decid pursu bid bid karxt dose
subsequ clinic develop trial karxt schizophrenia
trial karxt acut psychosi schizophrenia
conduct random double-blind placebo-control trial karxt
adult patient schizophrenia experienc acut psychosi hospit
diagnosi criteria appli dsm-v inclus requir baselin panss score
patient baselin characterist evenli split karxt placebo group
patient random karxt placebo washed-out
antipsychot therapi enter treatment period dose administr
bid karxt day bid day bid
option titrat base toler bid day primari endpoint
chang panss total score baselin week karxt vs placebo
secondari endpoint includ chang panss posit neg subscal
panss marder factor clinic global impressionsever cgi- cognit batteri
notabl trial design primari endpoint fundament similar prior trial
xanomelin schizophrenia histor registr trial approv sga
see potenti fda consid trial one two trial requir nda
exhibit trial karxt schizophrenia design patient baselin
top-line result novemb demonstr efficaci highli statist signific
clinic meaning mean reduct panss total score week
highli statist signific efficaci secondari endpoint includ mean reduct
week panss posit subscal karxt vs placebo karxt
vs placebo panss neg subscal karxt vs placebo
karxt vs placebo panss marder factor karxt
vs placebo karxt vs placebo cgi- improv
karxt vs placebo observ statist separ endpoint
everi timepoint includ support rapid activ karxt
although statist signific observ secondari endpoint
percentag cgi- respond normal borderlin ill sever
seven-point scale observ direct support ratio karxt vs
placebo karxt vs placebo meta-analysi cohen effect size
primari endpoint placebo-adjust panss total score chang across registr
trial approv sga illustr cohen effect size karxt
compar favor view larg effect size karxt absolut panss total
score reduct week suffici cushion larger placebo effect
could like result heighten optim mean revers larger
sampl size next trial also view efficaci neg symptom distinct
exhibit trial karxt schizophrenia efficaci result
safeti toler result demonstr karxt well-toler consist
prior studi improv upon trial xanomelin schizophrenia
overal discontinu rate karxt group compar placebo group
number discontinu due trae equal patient group
notabl observ karxt patient titrat bid
higher dose bid base physician assess toler individu
patient compar placebo patient karxt patient
titrat back bid dose base toler compar
placebo patient overal trae rate karxt group vs placebo group
note observ trae mild/moder sever across karxt
placebo group view overal safeti toler profil karxt favor
highli competit current avail antipsychot
exhibit trial karxt schizophrenia safeti result
plan meet fda anticip initi trial
although consid posit trial potenti registr anticip
conduct two registr trial optim probabl success posit
result fulfil like requir suffici larg safeti databas note
subject fda feedback trial design reflect substanti design
trial larger sampl size conserv guid
power assumpt statist signific placebo-adjust chang
panss total score even similar sampl karxt placebo group
anticip conduct one studi us would replic trial
overlap site second trial global support potenti registr
geographi like eu would conduct staggered/parallel time-frame
view regulatori strategi prudent base histor preced approv
sga two posit registr trial indic schizophrenia adult
studi karxt elderli volunt drp
conduct random double-blind placebo-control studi karxt
elderli healthi volunt studi design similar prior mad studi
two week treatment potenti titrat day subject random
karxt multipl dose group placebo group flexibl dose enabl determin
maximum toler dose subject individu basi outcom measur
includ safeti toler dose inform potenti subsequ trial drp
believ favor safeti toler profil karxt elderli popul
critic pursu indic drp base common harm side-effect sga
current use off-label drp patient note syncop observ prior
trial ad observ incid syncop prior karxt trial
anticip on-going trial older patient similarli show syncop
expect overal safeti toler substanti improv xanomelin
initi studi expect result
antipsychot market size annual world-wide sale
expect grow base consensu estim view market size
suffici larg new entrant competit base moa data
exampl abilifi seroquel zyprexa reach histor peak sale
provid basi refer market forecast karxt believ
highli competit fresh market entrant schizophrenia drp uniqu moa
provid substanti favor toler even efficaci perceiv similarli
larg unmet need impli patient demand novel differenti altern
analyz consensu estim annual sale top antipsychot product
found impli forecast compound annual growth rate compound-annual-growth-rate
next year caplyta nuplazid roluperidon sale
exhibit consensu estim annual ww sale top antipsychot product
exhibit profil potenti competitor karxt
sale us mln invega sustenna nuplazid vraylar allergan rexulti otsuka invega trinza abilifi maintena otsuka caplyta risperd consta aristada othercompani sunovioncerevelcompound caplyta lumateperon nuplazid pimavanserin roluperidon antagonist postsynapt antagonist prefer antagonist invers agonist antagonist antagonist agonist agonist pamstatu approv market schizophrenia adult approv parkinson diseas psychosi pdp pend fda review drp potenti approv pivot schizophrenia neg symptom expect initi trial schizophrenia neg symptom on-going top-line data expect trial schizophrenia on-going primari complet date mad studi on-going schizophrenia adult patient primari complet date result panss chang week caplyta vs placebo view caplyta efficaci limit posit symptom schizophrenia view caplyta similar legaci sga base moa side-effect profil anticip fda approv pimavanserin drp creat regulatori preced benefit later compound view pimavanserin effiaci limit neg symptom schizophrenia view roluperidon effiaci limit neg symptom schizophrenia result panss chang week vs placebo view result competit complic background benzodiazepin moa may caus similar side-effect legaci sga known moa target schizophrenia early-stag compar competitor anticip posit data although suspect less favor differenti karuna therapeut
forecast karxt sale schizophrenia
forecast world-wide peak sale karxt schizophrenia base
market model schizophrenia patient estim schizophrenia adult
patient us diagnosi rate refractori rate soc therapi
defin address us patient popul karxt set
estim peak market penetr initi us annual net price
base nuplazid assum ex-u partnership royalti
po schizophrenia base recent complet trial strongli
posit result larg unmet need schizophrenia therapi efficaci
posit neg cognit symptom clean safeti toler profil
literatur histor trial psychiatri forecast launch estim
peak risk-adjust world-wide sale
exhibit market model us sale forecast karxt schizophrenia
forecast karxt sale drp
forecast world-wide peak sale karxt drp base
market model drp patient estim elderli dementia patient us
diagnosi rate preval psychosi symptom defin
address us patient popul estim peak market penetr
initi us annual net price equival karxt price schizophrenia
assum ex-u partnership royalti po drp base
support prior data pend toler data trial regulatori preced set
literatur histor trial psychiatri forecast launch
estim peak risk-adjust world-wide sale
exhibit market model us sale forecast karxt drp
us popul patient patient diagnos schizophrenia patient schizophrenia patient respond treatment market penetr price therapi net price sale us popul patient patient psychosi symptom diagnos patient psychosi treatment market penetr price therapi net price sale us outperform
exhibit market model us sale forecast karxt drp
karxt new chemic entiti coformul xanomelin trospium chlorid
xanomelin never approv regulatori author countri therefor
karxt elig regulatori exclus territori world-wide regulatori exclus
includ eight year us includ patent stay pediatr
extens anticip xanomelin becom avail outsid karxt
anda challeng would requir provid bioequival karxt coformul
four issu us patent one issu eu patent three pend applic across
japan hong kong canada cover method composit karxt expir
patent term extens pend us patent applic cover
coformul ratio pk provid addit potenti protect
licens intellectu properti xanomelin exchang mileston
payment tier royalti global net sale low-mid single-digit percent rang
licens karxt composit coformul patent right puretech health
exchang mileston payment royalti global net sale low single-digit
percent assum royalti rate puretech health respect
conserv assum karxt patent protect
total total revenu psychosi psychosi total revenu psychosi sale forecast dementia-relatedpsychosi sale forecast dementia-relatedpsychosi drp schizophrenia karuna
analyz comparison competitor
compani compar base size develop stage
view well-capit cash zero debt outstand
similarli valu compar peer group base sale
exhibit compar analysi rel peer group
companytickerpricemarket cap ev debt consensu revenuesacadia therapi neurosci consensu revenuess bubbl correl market cap outperform
sotp analysi valu karxt schizophrenia drp
estim npv indic appli wacc termin growth rate
consist dcf valuat appli respect probabl success
schizophrenia drp arriv probability-adjust
value-per-share estim cash balanc equat approxim
exhibit sotp analysi valu per share karxt schizophrenia drp
valu dcf methodolog use discount rate termin valu
growth rate base patent expir arriv price target
estim peak sale schizophrenia drp
appli po risk-adjust schizophrenia drp base
literatur current develop stage estim cash balanc
cash-burn expect runway least next three year
addit model pipelin expans karxt pain combin and/or
possibl indic provid potenti sourc addit upsid
exhibit dcf valuat methodolog
drug/indicationexpect launchpeak sale estim mm unadjust npv valueest probabl successp-adj npv mm p-adj valu sharekarxt equiti share outstand use valuat valu growth valu psychosi success karxt drpdiscount rateequ valu per sharetermin valu growth rateequ valu per shareprob success karxt schizophrenia karuna therapeut
exhibit incom statement forecast
karuna except per-shar data probabilitiy-adj product psychosi revenu goods- royalti ptchf- gross expens research adjust research develop share-bas compens total share-bas gener adjust sell gener administr share-bas compens total share-bas total share-bas compens exclud total oper oper incom interest income- interest incom expens earn tax incom tax expens benefit tax incom basic share outstand share outstand dilut sourc compani file oppenheim co estim outperform
exhibit statement forecast
karuna fy incom adjust stock-bas compens depreci accret debt non-cash interest income- non-cash interest incom chang fair valu deriv warrant expense- other- chang oper asset liabil account receivable- inventories- prepaid expens current account accru defer leas obligation- current liabilities- flow purchas market securities- sale market securities- proce matur market securities- purchas properti other- flow proce public offer common stock- proce issuanc convert prefer stock- proce issuanc convert payment financ costs- proce warrant exercises- proce stock option exercis employe stock issuances- repay short-term bank debt- proce note payabl net- payment debt principal- other- flow net increas decreas cash begin equival sourc compani file oppenheim co estim karuna
exhibit balanc sheet forecast
karuna asset cash market securities- account receivable- inventories- prepaid expens current total current properti restrict cash- long-term assets- toal liabilitiescurr liabil account accru defer leas oblig current portion- deriv note payabl current current liabilities- total current note payabl long-term defer leas oblig long-term portion- redeem convert prefer stock- long-term total prefer stock- common stock- addit paid-in accumul incom accomul comprehens incom loss total stockhold total liabil sourc compani file oppenheim co estim outperform
karuna discount except per-shar data revenu chang work valu growth valu psychosi oppenheim co estimatesprob success karxt drpdiscount rateequ valu per sharetermin valu growth rateequ valu per shareprob success karxt karuna
stock price compani mention report april
compani lly-nys cover
